28th Jun 2007 07:01
ABCAM Plc28 June 2007 For immediate release 28 June 2007 ABCAM PLC ("Abcam" or "the Company") Year-end Trading Update Cambridge, UK: Abcam plc (AIM: ABC), the rapidly growing bioscience company thatmarkets antibodies via its own online catalogue, is pleased to announce atrading update ahead of its results for the year ending 30 June 2007. Sales in the second half have continued their strong growth trend with theresult that the Company expects full-year sales to slightly exceed marketexpectations. Due to the stronger sales, together with slightly lower expenses,pre-tax profits will exceed market expectations by about 10 per cent. Abcam now has more than 33,000 products in its online catalogue, compared with23,200 at 30 June 2006. The Company is pleased to report that construction ofits high-throughput production facility in Cambridge was completed on scheduleand that operations have commenced. The facility, which is one of the world'smost advanced antibody production laboratories, is designed to produce anincreasing number of higher margin in-house products to add to Abcam's onlinecatalogue. It is expected that Abcam's results for the year ending 30 June 2007 will beannounced in mid September 2007. For further information please contact: Abcam + 44 (0) 1223 696000Jonathan Milner, Chief Executive OfficerEddie Powell, Chief Financial Officerwww.abcam.com Numis Securities + 44 (0) 20 7776 1500Michael MeadeJames Black Buchanan Communications + 44 (0) 20 7466 5000Mark Court / Mary-Jane Johnson Notes for editors: About Abcam plc Abcam is a producer and distributor of research-grade antibodies headquarteredin Cambridge, UK, with a US office located in Cambridge, Massachusetts. Abcamwas admitted to AIM in November 2005 and trades under the ticker symbol ABC.The Company produces and distributes its own and third party produced antibodiesto academic and commercial users throughout the world with product informationprovided and ordering available through the Company's website, www.abcam.com.The antibodies are sold under the Abcam brand name. The Company's vision is tobuild the largest online antibody resource in the world while also ensuring thatthe antibodies are of high quality and commercially viable. Abcam now has anonline catalogue of approximately 33,000 products, most of which are antibodies,from over 200 suppliers supported by up-to-date and detailed technical datasheets, which are created by the Company. The Company currently employs 120staff in its three operating companies. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
ABC.L